This study is in progress, not accepting new patients
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Allena Pharmaceuticals
- Links
- A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme ALLN-177, oral enzyme therapy for hyperoxaluria
- ID
- NCT03847090
- Phase
- Phase 3 Enteric Hyperoxaluria Research Study
- Study Type
- Interventional
- Participants
- At least 92 people participating
- Last Updated